About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

University of California San Diego and Deerfield Management Create Poseidon Innovation to Advance Disease-Curing Therapeutics

In its first public university partnership, Deerfield commits $65 million to accelerate UC San Diego drug development cycle

San Diego and New York – September 5, 2018 – University of California San Diego (UC San Diego) and Deerfield Management announce today the creation of Poseidon Innovation, LLC to advance disease-curing therapeutics. Through Deerfield’s $65‐million commitment in Poseidon, UC San Diego investigators will have the funding and support to weather risky early‐stage processes and expedite the drug‐development cycle, allowing patients to receive treatment faster.

The Poseidon Innovation partnership has the potential to further the high‐quality research that has placed UC San Diego 7th in the nation in research expenditures (according to NSF’s latest HERD rankings), with at least $1 billion in sponsored research annually for the past nine years. Poseidon leverages UC San Diego’s courage to dissect convention, and together with Deerfield, creates cross‐disciplinary, flexible approaches to advance research and break down silos that often cause roadblocks to advancement. Furthermore, Deerfield may make additional capital investments through spin‐off companies that emerge from Poseidon projects and show commercial potential.

Projects that enter Poseidon will be directed by a joint steering committee and have access to sufficient funding for a full drug development program. Investigational New Drug (IND) application‐enabling work will be done in labs on campus and externally. Initially, Paul Roben, associate vice chancellor for the Office of Innovation & Commercialization; James McKerrow, dean of Skaggs School of Pharmacy and Pharmaceutical Sciences; and Alan Saltiel, director of the Institute for Diabetes and Metabolic Health from UC San Diego will be on the joint steering committee with members of the Deerfield team.

“Poseidon Innovation provides a new pathway for our investigators to push their discoveries to fruition. The funding and drug development support provided can enable therapies to get to patients faster. In breaking the traditional rules of discovery, we can create a greater impact and a better future for patients,” stated Sandra A. Brown, vice chancellor for research at UC San Diego.

“The motivation and audacity to pursue novel ways to advance science and improve patient treatment is palpable on the UC San Diego campus. This drive, combined with world‐renowned scientists, makes Poseidon an exciting endeavor and partnership. We look forward to helping create remarkable new therapeutics,” stated James Flynn, managing partner of Deerfield Management.

Roben commented, “Poseidon fills a gap in early‐stage funding and support that many novel projects struggle to fill. This program will allow more projects to reach a critical decision point and, if successful, projects will have full funding to complete all studies necessary to file an IND application. This alone should provide investigators with tremendous time savings as the struggle for funding will be over. We look forward to many successful programs.”

About University of California San Diego

At the University of California San Diego, we constantly push boundaries and challenge expectations. Established in 1960, UC San Diego has been shaped by exceptional scholars who aren’t afraid to take risks and redefine conventional wisdom. Today, as one of the top 15 research universities in the world, we are driving innovation and change to advance society, propel economic growth and make our world a better place. Learn more at

About Deerfield

Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.

For more information, please visit


Deerfield Management Company
Karen Heidelberger, 212‐551‐1600
[email protected]

UC San Diego
Michelle Franklin, 858‐534‐8564
[email protected]